Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05812404
Other study ID # DW_DWP14012109
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date October 26, 2022
Est. completion date June 16, 2023

Study information

Verified date April 2023
Source Daewoong Pharmaceutical Co. LTD.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A randomized, open-label, three-period, three-sequence, multiple dosing crossover, phase 1 clinical trial to evaluate the effect of DWP14012 on the pharmacokinetics of DWC202201 after co-administration of DWP14012 and DWC202201 in healthy subjects


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 36
Est. completion date June 16, 2023
Est. primary completion date March 28, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years to 50 Years
Eligibility Inclusion Criteria: - Healthy adults aged = 19 and = 50 years at screening - Subjects with a body weight = 50.0 kg to = 90.0 kg with a body mass index (BMI) of = 18.0 kg/m2 to = 27.0 kg/m2 at screening ? BMI (kg/m2) = body weight (kg)/[height (m)]2 - Subjects who voluntarily decided to participate in the study and provided written consent to follow precautions after receiving a sufficient explanation on this study and fully understanding the information - Subjects who are eligible to participate in the study at the discretion of the investigator by physical examination, laboratory tests, and investigator questioning, etc. Exclusion Criteria: - Subjects with a disease or a history related to hepatobiliary system, kidney(severe kidney disorder ect.), nervous system, respiratory system, digestive system, endocrine system, hematology system, circulatory system(Heart failure, Torsades de pointes ect.), unrinary system, psychiatry ect. - Subjects with digestive disease(gastrointestinal ulcers, gastritis, stomach cramps, gastroesophageal disease, Crohn's disease) or history of surgery(except appendectomy, hernia surgery) which can affect on saftey and pharmacodynamics - Subjects with hypersensitivity or history of clinically significant hypersensitivity to drugs including potassium competitive acid blocker [P-CAB] class, aspirin, antibiotics, etc. - Subjects with hereditary disorders including galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption, etc. - Subjects with history of inherited muscle disorders - Subjects with a history of drug abuse or a positive result of using abusive drugs in the urine drug screen - Subjects who participated in other clinical trials (including bioequivalence studies) within 6 months prior to the first scheduled dose of the IP - Subjects who donated whole blood within 2 months, donated blood components within 1 month, or received blood transfusion within 1 month prior to the first scheduled dose - Subjects who are unable to refrain from grapefruit-containing products from 3 days prior to the first scheduled dose until last discharge from hospital - Subjects or their spouses or partners who are unable to use medically acceptable appropriate double-method of contraception or medically acceptable contraception throughout the study period and for at least 4 weeks after the last IP administration - Subjects who are unable to refrain from smoking(>10pieces/day) from 3 days prior to the first scheduled dose until last discharge from hospital - Subjects with alchoholic disorders or subjects who are unable to refrain from drinking(>21units/week) from 3 days prior to the first scheduled dose until last discharge from hospital - Subjects who are unable to refrain from caffein(>5units/day) from 3 days prior to the first scheduled dose until last discharge from hospital

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
DWP14012
Potassium-competitive acid blocker
DWC202201
Atorvastatin Calcium Trihydrate

Locations

Country Name City State
Korea, Republic of Seoul National University Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
Daewoong Pharmaceutical Co. LTD.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Atorvastatin Peak Plasma Concentration at steady state (Cmax,ss) after DWC202201 multiple dosing [Time Frame: up to 64 days]
Primary Atorvastatin Area under the plasma concentration versus time curve at steady state (AUCinf, ss) after DWC202201 multiple dosing [Time Frame: up to 64 days]
Secondary Atorvastatin Area under the plasma concentration extrapolated to infinity at steady state (AUC,ss) after DWC202201 multiple dosing [Time Frame: up to 64 days]
Secondary Atorvastatin Time to peak drug concentration at staedy state (Tmax, ss) after DWC202201 multiple dosing [Time Frame: up to 64 days]
Secondary Atorvastatin Terminal Half-life at steady state (T1/2,ss) after DWC202201 multiple dosing [Time Frame: up to 64 days]
Secondary Atorvastatin Apparent total body clearance at steady state (CLss/F) after DWC202201 multiple dosing [Time Frame: up to 64 days]
Secondary Atorvastatin Apparent volume of distribution at steady state (Vd,ss/F) after DWC202201 multiple dosing [Time Frame: up to 64 days]
Secondary Atorvastatin active metabolite Area under the plasma concentration versus time curve at steady state (AUCinf, ss) after DWC202201 multiple dosing [Time Frame: up to 64 days]
Secondary Atorvastatin active metabolite Terminal Half-life at steady state (T1/2,ss) after DWC202201 multiple dosing [Time Frame: up to 64 days]
Secondary Atorvastatin active metabolite An estimate of the total body clearance at steady state (CL ss/F) after DWC202201 multiple dosing [Time Frame: up to 64 days]
Secondary Atorvastatin active metabolite Apparent volume of distribution at steady state (Vd,ss/F) after DWC202201 multiple dosing [Time Frame: up to 64 days]
Secondary Atorvastatin active metabolite metabolic ratio after DWC202201 multiple dosing [Time Frame: up to 64 days]
Secondary Fexuprazan Peak Plasma Concentration (Cmax) after DWP14012 single dosing [Time Frame: up to 64 days]
Secondary Fexuprazan Area under the plasma drug concentration-time curve from 0 to tau (AUCtau) after DWP14012 single dosing [Time Frame: up to 64 days]
Secondary Fexuprazan Area under the plasma drug concentration-time curve from 0 to infinity(AUCinf) after DWP14012 single dosing [Time Frame: up to 64 days]
Secondary Fexuprazan The time of peak concentration (Tmax) after DWP14012 single dosing [Time Frame: up to 64 days]
Secondary Fexuprazan Terminal Half-life (t1/2) after DWP14012 single dosing [Time Frame: up to 64 days]
Secondary Fexuprazan Apparent Clearance (CL/F) after DWP14012 single dosing [Time Frame: up to 64 days]
Secondary Fexuprazan Apparent Volume of Distribution After extravascular administration (Vd/F) after DWP14012 single dosing [Time Frame: up to 64 days]
Secondary Fexuprazan Peak Plasma Concentration at steady state (Cmax,ss) after DWP14012 multiple dosing [Time Frame: up to 64 days]
Secondary Fexuprazan Area under the plasma drug concentration-time curve from 0 to tau at steady state (AUCtau,ss) after DWP14012 multiple dosing [Time Frame: up to 64 days]
Secondary Fexuprazan Area under the plasma drug concentration-time curve from 0 to infinity at steady state (AUCinf,ss) after DWP14012 multiple dosing [Time Frame: up to 64 days]
Secondary Fexuprazan Time of Maximum Concentration at steady state (Tmax,ss) after DWP14012 multiple dosing [Time Frame: up to 64 days]
Secondary Fexuprazan Terminal Half-life at steady state (t1/2,ss) after DWP14012 multiple dosing [Time Frame: up to 64 days]
Secondary Fexuprazan An estimate of the total body clearance at steady state (CL ss/F) after DWP14012 multiple dosing [Time Frame: up to 64 days]
Secondary Fexuprazan Aapparent volume of distribution after extravascular administration at steady state (Vd,ss/F) after DWP14012 multiple dosing [Time Frame: up to 64 days]
Secondary Fexuprazan Accumulation ratio after DWP14012 multiple dosing [Time Frame: up to 64 days]
Secondary Fexuprazan active metabolite Peak Plasma Concentration (Cmax) after single dosing [Time Frame: up to 64 days]
Secondary Fexuprazan active metabolite Area under the plasma drug concentration-time curve from 0 to tau (AUCtau) after single dosing [Time Frame: up to 64 days]
Secondary Fexuprazan active metabolite Area under the plasma concentration extrapolated to infinity (AUCinf) after single dosing [Time Frame: up to 64 days]
Secondary Fexuprazan active metabolite The time of peak concentration (Tmax) after single dosing [Time Frame: up to 64 days]
Secondary Fexuprazan active metabolite metabolic ratio after single dosing [Time Frame: up to 64 days]
Secondary Fexuprazan active metabolite Peak Plasma Concentration at steady state (Cmax,ss) after multiple dosing [Time Frame: up to 64 days]
Secondary Fexuprazan active metabolite AUCtau,ss AUCinf,ss Tmax,ss metabolic ratio [Time Frame: up to 64 days]
Secondary Fexuprazan active metabolite Area under the plasma drug concentration-time curve from 0 to tau at steady state (AUCtau,ss) after multiple dosing [Time Frame: up to 64 days]
Secondary Fexuprazan active metabolite Area under the plasma concentration extrapolated to infinity at steady state (AUCinf,ss) after multiple dosing [Time Frame: up to 64 days]
Secondary Fexuprazan active metabolite The time of peak concentration at steady state (Tmax,ss) after multiple dosing [Time Frame: up to 64 days]
Secondary Fexuprazan active metabolite metabolic ratio after multiple dosing [Time Frame: up to 64 days]
See also
  Status Clinical Trial Phase
Completed NCT05574374 - Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy Subjects Phase 1
Completed NCT04557397 - Fruquintinib CYP3A Inhibitor and Inducer Study Phase 1
Completed NCT06031454 - Drug-durg Interaction of Leritrelvir(RAY1216) With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin Phase 1
Completed NCT05137600 - A Drug-Drug Interaction Study Between ATI-2173 and Midazolam or Clarithromycin in Healthy Subjects Phase 1
Recruiting NCT06119958 - Drug-drug Interactions Between DWC202313 and DWC202314 in Healthy Subjects Phase 1
Completed NCT04606537 - Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects Phase 1
Completed NCT04939467 - Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers Phase 1
Completed NCT04542252 - Drug-Drug Interaction Study of Intravenous Administration of SyB V-1901 and Cyclosporine in Japanese Healthy Subjects Phase 1
Enrolling by invitation NCT06037564 - B-free Multistage Trial Phase 4
Completed NCT05123820 - Pharmacokinetics of Omeprazole and Midazolam When Co-administered With ACT-1014-6470 Phase 1
Recruiting NCT04840862 - Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor Phase 4
Completed NCT04814498 - Drug-Drug Interaction (DDI) Study in Healthy Volunteers Phase 1
Completed NCT01350921 - Evaluation of the Drug-drug Interaction Between Ticagrelor and Venlafaxine When Taken Together in Healthy Volunteers Phase 1
Completed NCT03103568 - A Study to Investigate the Potential Influence of Nitisinone on the Metabolism and the Transport of Other Drugs in Healthy Volunteers Phase 1
Completed NCT04840641 - Flucloxacillin as an Inducer of CYP-enzymes Phase 1
Completed NCT05845567 - The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2) Phase 1
Completed NCT05304845 - Drug-drug Interactions Between DWP14012 and Aspirin in Healthy Subjects Phase 1
Completed NCT05860114 - Givinostat and Metabolites Pharmacokinetics in Urine and Plasma (Part 3) Phase 1
Completed NCT04776499 - Possible Effects of Propylthiouracil, Riociguat and Perphenazine on Circulation of Healthy Volunteers Phase 1
Completed NCT03909529 - Drug-drug Interaction (DDI) Study of Spironolactone (Perpetrator) and Digoxin (Substrate Drug) Phase 1